SG11202100194VA - Antigen purification method - Google Patents
Antigen purification methodInfo
- Publication number
- SG11202100194VA SG11202100194VA SG11202100194VA SG11202100194VA SG11202100194VA SG 11202100194V A SG11202100194V A SG 11202100194VA SG 11202100194V A SG11202100194V A SG 11202100194VA SG 11202100194V A SG11202100194V A SG 11202100194VA SG 11202100194V A SG11202100194V A SG 11202100194VA
- Authority
- SG
- Singapore
- Prior art keywords
- purification method
- antigen purification
- antigen
- purification
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18551—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862712280P | 2018-07-31 | 2018-07-31 | |
PCT/IB2019/056501 WO2020026147A1 (en) | 2018-07-31 | 2019-07-30 | Antigen purification method |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100194VA true SG11202100194VA (en) | 2021-02-25 |
Family
ID=68084873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100194VA SG11202100194VA (en) | 2018-07-31 | 2019-07-30 | Antigen purification method |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210292395A1 (ko) |
EP (1) | EP3829618A1 (ko) |
JP (1) | JP2021532764A (ko) |
KR (1) | KR20210038919A (ko) |
CN (1) | CN112566654A (ko) |
AU (1) | AU2019313502A1 (ko) |
BR (1) | BR112020027090A2 (ko) |
CA (1) | CA3106304A1 (ko) |
EA (1) | EA202190136A1 (ko) |
IL (1) | IL280140A (ko) |
MX (1) | MX2021001129A (ko) |
SG (1) | SG11202100194VA (ko) |
WO (1) | WO2020026147A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022023814A (ja) * | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産された三量体型のrsvタンパク質の精製方法 |
JP2022023813A (ja) * | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産されたrsvタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良 |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
CN116621948B (zh) * | 2023-07-21 | 2023-10-13 | 易康生物(苏州)有限公司 | 一种重组呼吸道合胞病毒f蛋白的纯化工艺方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
EP0362278A4 (en) | 1987-06-05 | 1990-05-14 | Us Health | FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER. |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
BRPI0716959A2 (pt) | 2006-09-26 | 2013-10-29 | Infectious Disease Res Inst | Composição de vacina contendo adjuvante sintético |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
JP5951634B2 (ja) | 2010-12-14 | 2016-07-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | マイコバクテリウム抗原性組成物 |
KR20220139415A (ko) | 2013-03-13 | 2022-10-14 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 선융합(prefusion) RSV F 단백질 및 이의 용도 |
CN109069611B (zh) * | 2016-03-29 | 2022-11-04 | 美国政府(由卫生和人类服务部的部长所代表) | 取代修饰的融合前rsv f蛋白及其用途 |
-
2019
- 2019-07-30 AU AU2019313502A patent/AU2019313502A1/en not_active Abandoned
- 2019-07-30 SG SG11202100194VA patent/SG11202100194VA/en unknown
- 2019-07-30 US US17/262,098 patent/US20210292395A1/en active Pending
- 2019-07-30 CN CN201980051001.XA patent/CN112566654A/zh active Pending
- 2019-07-30 JP JP2021504800A patent/JP2021532764A/ja active Pending
- 2019-07-30 CA CA3106304A patent/CA3106304A1/en active Pending
- 2019-07-30 KR KR1020217005566A patent/KR20210038919A/ko unknown
- 2019-07-30 WO PCT/IB2019/056501 patent/WO2020026147A1/en unknown
- 2019-07-30 MX MX2021001129A patent/MX2021001129A/es unknown
- 2019-07-30 EA EA202190136A patent/EA202190136A1/ru unknown
- 2019-07-30 EP EP19779554.5A patent/EP3829618A1/en active Pending
- 2019-07-30 BR BR112020027090-3A patent/BR112020027090A2/pt unknown
-
2021
- 2021-01-12 IL IL280140A patent/IL280140A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019313502A1 (en) | 2021-01-28 |
JP2021532764A (ja) | 2021-12-02 |
US20210292395A1 (en) | 2021-09-23 |
CN112566654A (zh) | 2021-03-26 |
WO2020026147A1 (en) | 2020-02-06 |
IL280140A (en) | 2021-03-01 |
EP3829618A1 (en) | 2021-06-09 |
MX2021001129A (es) | 2021-07-02 |
CA3106304A1 (en) | 2020-02-06 |
EA202190136A1 (ru) | 2021-05-14 |
KR20210038919A (ko) | 2021-04-08 |
BR112020027090A2 (pt) | 2021-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201808474D0 (en) | Method | |
GB201800298D0 (en) | Method | |
GB201807793D0 (en) | Method | |
GB201808554D0 (en) | Method | |
IL280140A (en) | Antigen purification method | |
GB201809323D0 (en) | Method | |
GB201805876D0 (en) | Method | |
GB201800558D0 (en) | Method | |
GB201808663D0 (en) | Method | |
GB201804277D0 (en) | Method | |
GB2579197B (en) | Abatement method | |
GB201806240D0 (en) | Method | |
GB201803750D0 (en) | Method | |
IL277056A (en) | Methods for purifying antibodies | |
GB2584562B (en) | Purification method | |
GB201808558D0 (en) | Method | |
GB201807788D0 (en) | Method | |
GB201807041D0 (en) | Method | |
GB201803183D0 (en) | Method | |
GB201802653D0 (en) | Method | |
GB201801169D0 (en) | Method | |
GB201800187D0 (en) | Method | |
IL276816A (en) | Antibody purification | |
IL287609A (en) | Purification method | |
GB201808556D0 (en) | Method |